Association of genetic polymorphisms in vascular endothelial growth factor with susceptibility to coronary artery disease: a meta–analysis

Ma, Wen-Qi; Wang, Ying; Han, Xi-Qiong; Zhu, Yi; Liu, Nai-Feng

doi:10.1186/s12881-018-0628-3

Table 1 Characteristics of the individual studies included in the meta–analysis

From: Association of genetic polymorphisms in vascular endothelial growth factor with susceptibility to coronary artery disease: a meta–analysis

Study	Country	Ethnicity	Disease	Control Source	Genotyping Methods	Sample Size Cases/Controls	Genotype Distribution		P_HWE	NOS
Study	Country	Ethnicity	Disease	Control Source	Genotyping Methods	Sample Size Cases/Controls	Cases	Controls	P_HWE	NOS
rs699947							AA/AC/CC	AA/AC/CC
Biselli 2008²³	Brazil	Caucasian	CAD	HB	PCR	175/108	32/96/47	27/51/30	0.569	6
Kangas–Kontio 2009²⁵	Finland	Caucasian	MI	HB	TaqMan	188/218	64/87/37	77/101/40	0.498	7
Chen 2011²⁶	UK	Caucasian	MI	PB	PCR–RFLP	46/372	10/34/2	100/167/105	0.050	8
Amoli 2012²⁷	Iran	Asian	CAD	HB	PCR	50/50	9/26/15	14/27/9	0.520	6
Cui 2013²⁸	China	Asian	CAD	HB	PCR	242/253	27/78/137	12/69/172	0.148	6
Gu 2013²⁹	China	Asian	CAD	HB	MassARRAY	427/472	30/178/219	31/174/267	0.713	6
Li 2016²²	China	Asian	CAD	PB	PCR	533/533	180/250/103	217/237/79	0.280	8
Liu 2016³¹	China	Asian	CAD	PB	PCR	810/805	275/381/154	339/345/121	0.03	8
rs2010963							GG/GC/CC	GG/GC/CC
Petrovic 2007²⁴	Slovenia	Caucasian	MI	PB	PCR	143/228	42/76/25	103/104/21	0.470	7
Kangas–Kontio 2009²⁵	Finland	Caucasian	MI	HB	TaqMan	186/218	113/61/12	143/67/8	0.966	7
Chen 2011²⁶	UK	Caucasian	MI	PB	PCR–RFLP	46/372	26/19/1	174/159/39	0.765	8
Cui 2013²⁸	China	Asian	CAD	HB	PCR	242/253	75/102/65	104/114/35	0.675	6
Gu 2013²⁹	China	Asian	CAD	HB	MassARRAY	419/468	144/215/60	154/225/89	0.672	6
Douvaras 2013³²	Greece	Caucasian	MI	HB	PCR–RFLP	102/98	37/49/16	29/55/14	> 0.050	7
Moradzadegan 2015³⁰	Iran	Asian	CAD	HB	PCR–RFLP	141/369	43/65/33	85/197/87	0.193	7
Han 2015²¹	China	Asian	CAD	HB	MassARRAY	144/150	69/49/26	86/54/10	0.701	6
Li 2016²²	China	Asian	CAD	PB	PCR	533/533	50/233/250	71/239/223	0.583	8
Nia 2017³³	Iran	Asian	CAD	HB	TaqMan	347/173	167/135/45	102/63/8	> 0.050	7
rs3025039							CC/CT/TT	CC/CT/TT
Biselli 2008²³	Brazil	Caucasian	CAD	HB	PCR	175/108	133/36/6	83/23/2	0.783	6
Kangas–Kontio 2009²⁵	Finland	Caucasian	MI	HB	TaqMan	187/218	140/42/5	155/56/7	0.488	7
Chen 2011²⁶	UK	Caucasian	MI	PB	PCR–RFLP	46/372	37/8/1	264/95/13	0.229	8
Cui 2013²⁸	China	Asian	CAD	HB	PCR	242/253	133/95/14	159/86/8	0.373	6
Gu 2013²⁹	China	Asian	CAD	HB	MassARRAY	430/473	272/142/16	300/159/14	0.194	6
Douvaras 2013³²	Greece	Caucasian	MI	HB	PCR–RFLP	102/98	68/30/4	69/27/2	> 0.050	7
Han 2015²¹	China	Asian	CAD	HB	MassARRAY	144/150	84/55/5	115/31/4	0.290	6
Liu 2016³¹	China	Asian	CAD	PB	PCR	810/805	472/308/30	617/167/21	0.020	8
rs1570360							GG/GA/AA	GG/GA/AA
Biselli 2008²³	Brazil	Caucasian	CAD	HB	PCR	175/108	96/61/18	57/38/13	0.104	6
Cui 2013²⁸	China	Asian	CAD	HB	PCR	242/253	151/79/12	172/69/12	0.148	6
Liu 2016³¹	China	Asian	CAD	PB	PCR	810/805	54/370/386	137/456/212	> 0.050	8

Abbreviations: CAD coronary artery disease; MI myocardial infarction; PCR polymerase chain reaction; PCR–RFLP polymerase chain reaction-restriction fragment length polymorphism; HWE Hardy–Weinberg equilibrium; PB population–based; HB hospital–based; NOS Newcastle–Ottawa quality scale; UK the United Kingdom

Back to article page

ISSN: 1471-2350

Contact us

General enquiries: ORSupport@springernature.com

BMC Medical Genetics

Contact us